Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin

The stable introduction of a functional β-globin gene in haematopoietic stem cells could be a powerful approach to treat β-thalassaemia and sickle-cell disease. Genetic approaches aiming to increase normal β-globin expression in the progeny of autologous haematopoietic stem cells might circumvent the limitations and risks of allogeneic cell transplants. However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human β-globin gene when it was linked to minimal regulatory sequences. Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human β-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine α-globin and two human βA-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In β-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.

[1]  S. Rivella,et al.  The cHS4 Insulator Increases the Probability of Retroviral Expression at Random Chromosomal Integration Sites , 2000, Journal of Virology.

[2]  F. Grosveld,et al.  The Dynamics of Globin Gene Expression and Gene Therapy Vectors , 1998, Annals of the New York Academy of Sciences.

[3]  M. Vidal,et al.  A dominant control region from the human β-globin locus conferring integration site-independent gene expression , 1989, Nature.

[4]  M. Groudine,et al.  Looping versus linking: toward a model for long-distance gene activation. , 1999, Genes & development.

[5]  S. Rivella,et al.  Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. , 1998, Seminars in hematology.

[6]  B. Torbett,et al.  Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. , 1999, Science.

[7]  F. Oski,et al.  Hematology of Infancy and Childhood , 1974 .

[8]  H. Raftopoulos,et al.  Long-Term Transfer and Expression of the Human β-Globin Gene in a Mouse Transplant Model , 1997 .

[9]  P. Detloff,et al.  A mouse model for beta 0-thalassemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. C. Forrester,et al.  Evidence for a locus activation region: the formation of developmentally stable hypersensitive sites in globin-expressing hybrids. , 1987, Nucleic acids research.

[11]  D. Higgs.  Do LCRs Open Chromatin Domains? , 1998, Cell.

[12]  D. Tuan,et al.  Mutagenesis of retroviral vectors transducing human beta‐globin gene and beta‐globin locus control region derivatives results in stable transmission of an active transcriptional structure. , 1994, The EMBO journal.

[13]  W. C. Forrester,et al.  High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. D. Engel,et al.  Synergistic regulation of human beta-globin gene switching by locus control region elements HS3 and HS4. , 1995, Genes & development.

[15]  P. Giardina,et al.  Bone Marrow Transplantation for Homozygous β‐Thalassemia: The Memorial Sloan‐Kettering Cancer Center Experience , 1998, Annals of the New York Academy of Sciences.

[16]  M. Sadelain.  GENETIC TREATMENT OF THE HAEMOGLOINOPATHIES: RECOMBINATIONS AND NEW COMBINATIONS , 1997, British journal of haematology.

[17]  L. Luzzatto,et al.  Synthesis of haemoglobins specified by allelic genes in human heterozygotes. , 1971, Nature: New biology.

[18]  F. Grosveld,et al.  Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Tuan,et al.  The "beta-like-globin" gene domain in human erythroid cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Luigi Naldini,et al.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.

[21]  G. Kollias,et al.  Position-independent, high-level expression of the human β-globin gene in transgenic mice , 1987, Cell.

[22]  S. Le,et al.  The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA , 1989, Nature.

[23]  A. Mutero,et al.  The human beta globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. , 1997, Blood.

[24]  J. D. Engel,et al.  Looping, Linking, and Chromatin Activity New Insights into β-globin Locus Regulation , 2000, Cell.

[25]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[26]  G. Stamatoyannopoulos,et al.  The molecular basis of blood diseases , 1987 .

[27]  M. Sadelain,et al.  Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. , 1997, Blood.

[28]  D J Weatherall,et al.  The thalassemia syndromes. , 2016, Texas reports on biology and medicine.

[29]  J. Hofrichter,et al.  A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity. , 1995, Blood.

[30]  I. Chen,et al.  Lentiviral Vectors--the Promise of Gene Therapy Within Reach? , 1999, Science.